Jazz Pharmaceuticals (NASDAQ: JAZZ) net income
Jazz Pharmaceuticals reported a net loss of $356.1m for fiscal 2025; in fiscal 2024 it reported a net profit of $560.1m. Earnings per share were −$5.84.
Jazz Pharmaceuticals's best year of the last 10 was fiscal 2024. The biggest drop was in fiscal 2020, −54.4%. It reported a loss in 3 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$356.1m | −163.6% | −8.3% | −$5.84 |
| 2024 | $560.1m | +35.0% | 13.8% | $9.06 |
| 2023 | $414.8m | — | 10.8% | $6.55 |
| 2022 | −$224.1m | — | −6.1% | −$3.58 |
| 2021 | −$329.7m | −238.2% | −10.7% | −$5.52 |
| 2020 | $238.6m | −54.4% | 10.1% | $4.28 |
| 2019 | $523.4m | +17.1% | 24.2% | $9.22 |
| 2018 | $447.1m | −8.4% | 23.6% | $7.45 |
| 2017 | $487.8m | +22.9% | 30.1% | $8.13 |
| 2016 | $396.8m | — | 26.7% | $6.56 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Jazz Pharmaceuticals net income compared with its sector
By net income for its latest fiscal year, Jazz Pharmaceuticals ranks 458th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Jazz Pharmaceuticals, −8.3%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 456th | Immunitybio | −$351.4m | −310.2% |
| 457th | Arcus Biosciences | −$353.0m | −142.9% |
| 458th | Jazz Pharmaceuticals | −$356.1m | −8.3% |
| 459th | Bausch & Lomb | −$360.0m | −7.1% |
| 460th | Myriad Genetics | −$365.9m | −44.4% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Jazz Pharmaceuticals
- How much did Jazz Pharmaceuticals earn in fiscal 2025?
- Jazz Pharmaceuticals reported a net loss of $356.1m for fiscal 2025. In fiscal 2024 it reported a net profit of $560.1m.
- What are the earnings per share of Jazz Pharmaceuticals?
- They were −$5.84 in fiscal 2025, compared with $9.06 in fiscal 2024.
- What was the most profitable year for Jazz Pharmaceuticals?
- Of its last 10 fiscal years, fiscal 2024, with $560.1m.
- Where does Jazz Pharmaceuticals rank in its sector by net income?
- It ranks 458th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Jazz Pharmaceuticals come from?
- From the annual report (Form 10-K) that Jazz Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Jazz Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Jazz Pharmaceuticals: the Jazz Pharmaceuticals page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.